Novo Nordisk says diabetes drug Victoza superior to Merck rival
COPENHAGEN, April 6 (Reuters) - Danish Novo Nordisk , the world's biggest insulin producer, said on Friday it had received a product label update for diabetes drug Victoza to include data showing superior efficacy when compared with rival drug Januvia from Merck.
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here